JAN 07, 2019 11:36 AM PST

Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer

WRITTEN BY: Carmen Leitch

Between twelve and seventeen percent of all breast cancer cases are triple-negative, a highly aggressive type. It lacks three common cancer therapeutic targets: human epidermal growth factor receptor 2 (HER2) and the progesterone (PR) and estrogen receptors (ER). Now researchers have created an experimental therapy for this deadly cancer, which was able to slow the metastasis of triple-negative breast cancer in a mouse model. The therapeutic protein, Tinagl1, can block two main pathways that breast cancer cells use to grow and metastasize, and is based on a natural protein. The findings were reported in Cancer Cell.

Treatment with recombinant Tinagl1 protein significantly suppressed lung metastasis, as shown by the blue arrows in mice with (right) or without (left) Tinagl1 treatment. / Credit: Image courtesy of Yibin Kang et al., Princeton University

"People have tried to block the spread of this form of cancer, but attempts so far have failed because if you try one approach, the cancer cells compensate by finding a way to escape," noted the senior author of the work Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology at Princeton University and associate director for consortium research at the Rutgers Cancer Institute of New Jersey. "With this new approach, the treatment blocks both pathways at the same time. It is like having one stone that kills two birds."

There aren't many treatment options for patients with triple-negative breast cancer; there is a high chance of relapse, and the prognosis is poor. This cancer can also become resistant to treatment. This work shows that there may be an option for these individuals one day.

The scientists determined that Tinagl1 was able to stop the action of a protein called epidermal growth factor receptor gene (EGFR), which can promote tumor growth; if the gene that encodes for EGFR contains mutations, its activity increases, which fuels the growth of tumors and encourages cells to break off and migrate to other parts of the body. Therapeutics that target EGFR have not been particularly effective, potentially because cancer cells can use alternative pathways when EGFR is down. Tinagl1 was able to inhibit EGFR.

Image of human breast cancer conditionally reprogrammed cells in culture. Fluorescence red color represents MHC-I, and nuclei are shown in blue. / Credit: National Cancer Institute / Georgetown Lombardi Comprehensive Cancer Center / Ewa Krawczyk
 

The other pathway that was impacted by the therapeutic involves molecules called integrins, which help control cell movement and adhesion, and the shift to malignancy. Tinagl1 seems to disrupt integrin signaling by acting on another protein, focal adhesion kinase (FAK), which also functions in cell growth and migration as well as survival. These pathways are physiologically connected, with redundancy and compensation that enables cancer to evade treatment and grow aggressively, noted the scientists. The team found that both were inhibited by the experimental therapeutic.

Over 800 samples of human breast tumors were assessed for this work, which showed that tumor samples with lower Tinagl1 gene expression levels tended to come from advanced cancers and patients with shorter survival times. When tumors had high Tinagl1 expression levels, patients were more likely to have a good prognosis. In the triple-negative breast cancer samples, those differences were most pronounced.

After exposing mice with mammary tumors to the Tinagl1 protein for seven weeks, the researchers found that the growth of the primary tumors in the mice was inhibited, and there was less metastasis to the lungs. That treatment had an impact even when the metastasis had already started.

The researchers also investigated whether the Tinagl1 gene helps shield against the growth and spread of tumors by engineering tumor cells with high Tinagl1 gene expression. In mouse cancer cells, high expression levels reduced cancer growth and metastasis. However, mouse models have been cured of cancer before. This research does not necessarily mean this therapy will be effective in humans. Much more follow-up work will be needed.  

In the video above, Kang discusses breast cancer and metastasis.


Sources: AAAS/Eurekalert! via Princeton University, Cancer Cell

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 13, 2021
Genetics & Genomics
Explore Ways to Enhance Biomarker Discovery Research
MAY 13, 2021
Explore Ways to Enhance Biomarker Discovery Research
Enhance your existing research or discover new methods with a suite of NGS tools and techniques to find and characterize ...
MAY 15, 2021
Drug Discovery & Development
New Drug Blocks Critical Step in Malaria Life Cycle
MAY 15, 2021
New Drug Blocks Critical Step in Malaria Life Cycle
According to the World Health Organization (WHO), in 2019, there were approximately 229 million cases of malaria around ...
MAY 21, 2021
Space & Astronomy
Oxygen Conditions Needed for Emergence of Complex Life Discovered
MAY 21, 2021
Oxygen Conditions Needed for Emergence of Complex Life Discovered
For some time, scientists have supported the ‘Oxygen Control Hypothesis’. The theory states that higher leve ...
MAY 30, 2021
Microbiology
The Mechanics of a Gliding Microbe, Revealed
MAY 30, 2021
The Mechanics of a Gliding Microbe, Revealed
Humans have been able to use machines to master movement, but there are many organisms that can get around just fine on ...
MAY 31, 2021
Cell & Molecular Biology
Does Lactate Explain Why Exercise Can Relieve Depression?
MAY 31, 2021
Does Lactate Explain Why Exercise Can Relieve Depression?
Depression is one of the most common mental disorders and a frequent cause of disability around the world, impacting an ...
JUN 07, 2021
Cardiology
Researchers Find a Way to Improve Outcomes After a Heart Attack
JUN 07, 2021
Researchers Find a Way to Improve Outcomes After a Heart Attack
It's thought that in the United States, there is a heart attack once every 40 seconds, or that each year, about 80,0 ...
Loading Comments...